Pipeline
SHX-001 (Ketamine TDDS)
SHX-001 is a transdermal delivery of racemic ketamine for treatment of major depressive disorders (MDD).
SHX-005 (Racemic ketamine film)
SHX-005 is buccal film of racemic ketamine for treatment of major depressive disorders (MDD) and pain.
About US
understand us
Shenox aims to use good science to develop drug products that improve the quality of care and the quality of life to patients. Shenox focuses on the development of transdermal and transmucosal delivery of psychiatric medicines, including Major Depressive Disorder (MDD), neuropathic pain, and attention deficit hyperactivity disorder (ADHD).
The product, SHX-001, is targeted to reduce the adverse events and the addiction of ketamine for the treatment of depression, by means of innovative pharmacology design and precise transdermal delivery control. The Shenox team discovered that a gradual and prolonged ascending pharmacokinetics profile design of SHX-001 can bring an entirely new pharmacology of using ketamine to treat depression.
In parallel, Shenox has develop PigPerm, which is a comprehensive permeation and prediction platform, that can facilitate the translation of preclinical data to clinical study outcomes. Shenox also has an experienced team to streamline the 505(b)(2) regulatory path of approval, and the global commercialization of drug products.
Leave a Message
—
